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Summary
 Background: The purpose of this pilot study is to compare the efficacy and tolerance of azithromycin alone as 
opposed to standard treatment with sulfadiazine and pyrimethamine for active, non-vision-threat-
ening toxoplasmic retinochoroiditis.
 Material/Methods: We conducted a prospective, randomized, institutional clinical study comparing azithromycin to 
sulfadiazine and pyrimethamine for active, non-vision-threatening toxoplasmic retinochoroiditis. 
Nineteen out of 75 patients fulfilled inclusion criteria and were randomized into 2 treatment regi-
mens. Nine patients were treated with sulfadiazine and pyrimethamine and 10 patients with azithro-
mycin at a dose of 500 mg qd. Main outcome measures assessed were time to sharpening of lesion 
borders, time to lesion scarring, time to disease inactivity, and treatment tolerance.
 Results: Azithromycin monotherapy achieved lesion scarring and disease inactivity in all but 1 patient. 
Although no statistically significant difference was found between the 2 patient groups as regards 
main outcome measures for treatment efficacy, all median times to endpoints (days) were longer 
for the azithromycin group – time to sharpening of lesion borders on clinical evaluation (25.5 vs. 
24) and masked evaluation of photographs (30.5 vs. 24), time to lesion scarring on clinical evalu-
ation (73 vs. 47) and masked evaluation of photographs (71.5 vs. 36) and time to disease inactivi-
ty (73 vs. 49). Treatment tolerance was significantly better for the azithromycin group (p=0.0005).
 Conclusions: Azithromycin monotherapy at a dose of 500 mg per day was shown to be effective and well-tolerat-
ed for the treatment of active, non-vision-threatening toxoplasmic retinochoroiditis. Duration of 
treatment was clinically longer for the azithromycin group.
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Background
Toxoplasma gondii (T. gondii) can be considered a success-
ful parasite in view of its worldwide distribution and broad 
range of hosts. Toxoplasmic retinochoroiditis constitutes the 
most common type of posterior uveitis in otherwise healthy 
individuals, both in tertiary referral centers and in commu-
nity-based practices [1].
Substantial variations may be observed as regards the course 
of ocular toxoplasmic infection. While immunocompetent 
patients will almost invariably have only 1 focus of active ret-
inochoroiditis, irrespective of the number of scars, a mul-
tifocal pattern of disease manifestation in 1 or both eyes is 
more common in immunocompromised individuals [2]. 
Larger lesions are usually associated with longer disease du-
ration and an increased risk of complications [3].
The highly variable severity of ocular toxoplasmosis raises sig-
nificant issues regarding appropriate therapeutic strategies, 
and even the need for any treatment at all, in this self-limiting 
disease [4]. However, ocular toxoplasmosis can lead to severe 
visual impairment and an update of current practices in the 
management of the disease by Holland et al. [5] revealed a 
trend towards more aggressive treatment, with twice as many 
ophthalmologists intending to treat all cases. The majority 
of clinicians adhered to the “classical” approach, with dis-
crete courses of systemic drug therapy at times of active ret-
inochoroiditis, using combinations of multiple antiparasitic 
drugs and corticosteroids. For patients, particularly those with 
sight-threatening lesions located near the optic disc or the 
fovea, the combination of sulfadiazine and pyrimethamine 
remains the treatment of choice and has been considered 
the standard against which other regimens should be eval-
uated [5]. However, the potential toxicity of, or intolerance 
to, this drug combination has prompted research for alterna-
tive treatment regimens with better adverse events profiles.
Azithromycin is an acid-stable, orally administered macro-
lide antibiotic, structurally related to erythromycin, with a 
similar antimicrobial spectrum [6]. In vitro and in vivo effi-
cacy of azithromycin against T. gondii has been demonstrat-
ed in several animal models, as well as for the treatment of 
T. gondii encephalitis in patients with AIDS [7–16]. The ef-
ficacy of azithromycin alone [17] or in combination with 
pyrimethamine [18] and trimethoprim/sulfamethoxazole 
[19] in the management of active toxoplasmic retinocho-
roiditis has been demonstrated in previous studies. However, 
there has been no prospective randomized study compar-
ing the efficacy of azithromycin alone versus a combination 
of sulfadiazine and pyrimethamine for the treatment of ac-
tive toxoplasmic retinochoroiditis.
The purpose of this prospective, randomized pilot study 
is to compare the efficacy and tolerance of azithromycin 
alone versus the “classical” treatment regimen containing 
pyrimethamine and sulfadiazine, for the management of 
non-vision-threatening active toxoplasmic retinochoroiditis.
Material and Methods
We conducted a prospective, randomized, intention-to-treat, 
pilot study comparing the efficacy and tolerance of 2 treat-
ment regimens for active, non-vision-threatening toxoplasmic 
retinochoroiditis. Inclusion criteria consisted of ambulatory 
patients of both sexes, of more than 18 years of age at the 
time of diagnosis, presenting with an active, creamy-white 
focal retinal lesion, associated or not with an adjacent hy-
per-pigmented chorioretinal scar, in accordance with the 
clinical criteria established by Holland et al. [20]. Efficient 
contraception was mandatory for all female patients during 
treatment and for 6 months thereafter. Written informed 
consent was obtained from all patients.
Exclusion criteria included the presence of a toxoplasmic 
lesion less than 400 µm from the center of the macula or 
the optic disc; the presence of any other ocular morbidi-
ties; history of immunosuppressive, corticosteroid or antivi-
ral treatment within 14 days prior to inclusion in the study; 
known intolerance to any agent involved in the treatment 
regimens; patients with best corrected visual acuity of less 
than 1/120 on the Snellen chart in either eye; patients with 
known auditory defects, pregnancy, breast-feeding, or dia-
betes; and concomitant treatment with any 1 of the follow-
ing agents: ergotamine, fluconazole, cyclosporine, digox-
in, rifabutin or anti-coagulant medication.
Serum anti-T. gondii IgG and IgM antibodies were deter-
mined in all patients and found to be consistent with the 
clinical diagnosis of active toxoplasmic retinochoroiditis.
Patients were randomly assigned to 1 of the treatment arms 
(random choice by the patient of a sealed envelop containing 
the treatment regimen), consisting of either a combination 
of pyrimethamine (25 mg bid) and sulfadiazine (1000 mg 
tid for patients weighing less than 65 kg or 1000 mg qid for 
those weighing more than 65 kg) associated with folinic acid 
(15 mg qd) or azithromycin alone (500 mg qd). In addition, 
all patients were treated with prednisone 1 mg/kg/day ini-
tiated 3 days after the beginning of antiparasitic treatment 
with gradual tapering off by 5 mg every 3 days.
Patients were examined on day 1 and then every 15±5 days 
until disease inactivity. A further visit at 3 months from the be-
ginning of treatment was performed for all patients. Any dis-
comfort or adverse events were recorded. Patients were shown 
a numbered ruler (visual analogue score) and were asked 
to name and show the grading that best matched their level 
of comfort with treatment (0 – highest imaginable discom-
fort, 10 – no discomfort). On each visit, clinical assessment 
included visual acuity, slit-lamp biomicroscopy with grading 
of inflammatory reaction in the anterior chamber and vitre-
ous according to the SUN classification, tonometry, dilated 
fundus examination, and automated laser flare photometry 
(Kowa Laser Flare Meter FM-600). The time points of sharp-
ening of lesion borders, of lesion scarring, and of disease in-
activity, defined as a pigmented lesion with sharp borders and 
the absence of any inflammatory activity from the anterior 
chamber and the vitreous, were also noted. Treatment was 
discontinued as soon as disease was deemed inactive based 
on clinical evaluation. Fundus photographs of the retino-
choroidal lesion were taken on every visit. Fluorescein and 
indocyanine-green angiography following a standard proto-
col for posterior uveitis were performed on the initial visit 
and at the time point when disease inactivity was observed.
Laboratory examinations at baseline included complete 
blood count, serum glucose levels and renal and liver 
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biochemistry. A complete blood count was also performed 
on each visit for patients in the sulfadiazine/pyrimethamine 
treatment arm.
Fundus photographs were evaluated in a masked fashion by 
an independent ophthalmologist (KB). The time points of 
sharpening of lesion borders and of lesion scarring were re-
corded. Initial and final lesion size was measured using the 
appropriate application of the Imagenet software (TOPCON 
IMAGEnet i-base Basic version: 3.5.5) on fluorescein angi-
ography, both on initial visit and at the time point of dis-
ease inactivity. Late frames at 10 minutes were used for these 
measurements for all patients. Change in lesion size was cal-
culated from these measurements.
The criterion for failure of treatment was an increase in le-
sion size by more than 20% during the course of treatment, 
confirmed by evaluation of fundus photographs. In the case 
of treatment failure under azithromycin, patients would be 
switched to the standard regimen with sulfadiazine and py-
rimethamine. Criteria for treatment discontinuation were 
evidence of bone marrow depression on complete blood 
count (leucocyte count below 4,000/ml, platelet count below 
150,000/µl), a skin rash, or any other allergic reaction known 
to be potentially attributable to investigated treatment agents.
Statistical analysis was performed for the comparison of the 
2 groups of patients as regards baseline parameters and main 
outcome measures. We compared continuous variables with 
Mann-Whitney-Wilcoxon test and categorical variables with 
Fisher’s exact test. Adjusted p-values for multiple compar-
isons were also sought. Statistical level of significance was 
assigned for P values lower than 0.05.
Main outcome measures were percentage change in lesion 
size after treatment; time to sharpening of lesion borders 
on clinical evaluation and on masked evaluation of photo-
graphs; time to lesion scarring on clinical evaluation and 
on masked evaluation of photographs; time to disease inac-
tivity; treatment tolerance; and treatment intolerance lead-
ing to discontinuation of treatment.
The Bland-Altman method was employed to calculate the 
mean difference and 95% limits of agreement between the 2 
methods of measurement of time to lesion scarring (clinical 
evaluation and masked evaluation of fundus photographs).
Statistical analysis was performed with StataCorp. 2007. 
Stata Statistical Software: Release 10. College Station, TX: 
StataCorp LP.
Institutional Review Board (IRB)/ Ethics Committee ap-
proval of the University of Lausanne was obtained. The de-
scribed research adhered to the tenets of the Declaration of 
Helsinki (Protocol 26/03, Ethics Committee of the University 
of Lausanne). Swissmedic notification was performed for 
patients 14 to 19 according to Swiss regulations.
results
Out of 75 consecutive patients presenting with active toxoplas-
mic retinochoroiditis to the Uveitis Clinic of the Jules Gonin 
Eye Hospital over a 7-year period, 19 patients fulfilled the cri-
teria for inclusion in the study; 13 patients were excluded be-
cause they were under 18 years of age at the time of diagno-
sis, 10 had lesions close to the macula, 10 had lesions close to 
the optic disc, 7 patients declined participation in the study, 6 
were already being treated at the time they presented to our 
department, 3 patients had serious systemic comorbidities, 2 
had known allergy to pyrimethamine, 2 had 1 eye with visual 
acuity below 1/120 on the Snellen chart, there was 1 diabetic 
patient and 2 patients with known substantial auditory defect.
The epidemiological and clinical characteristics of the 
study sample at randomization are presented in Table 1. 
Nineteen patients were included in the study. Nine patients 
were randomized to the treatment regimen containing sul-
fadiazine/pyrimethamine and 10 to the regimen containing 
azithromycin. At randomization, no statistically significant 
difference as regards age, sex, symptom duration prior to 
initiation of treatment, initial lesion size, BCVA at presen-
tation or the presence of primary retinal lesions was found 
between the 2 treatment arms.
Group Azithromycin Group Sulfadiazine/ Pyrimethamine
N=10 N=9
Continuous variables Mean ±SD Mean ±SD p*
 Age (years)  40.9±17.1  47.7±19.1 0.595
 Symptoms duration (days)  14.6±19.1  8.6±9.6 0.412
 Lesion size (mm2)  6.3±4.5  9.2±5.1 0.121
 BCVA at presentation (logMAR)  0.18±0.15  0.18±0.19 0.934
Categorical variables n (%) n (%) p**
 Male sex 7 (70.0) 4 (44.4) 0.370
 Primary lesion 5 (50.0) 3 (33.3) 0.650
Table 1. Features of the patient sample at randomization in both treatment arms.
* value from Mann-Whitney-Wilcoxon test for independent samples; ** value derived from Fisher’s exact test; BCVA – best-corrected visual acuity.
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All the patients on sulfadiazine/pyrimethamine and all but 
1 patient on azithromycin exhibited favorable response to 
treatment, with lesion scarring and disease inactivity. With 
respect to main outcome measures of treatment efficacy, 
median times to specific end-points (sharpening of lesion 
borders, lesion scarring and disease inactivity) were longer 
in a clinically significant way for the azithromycin group, 
both on clinical evaluation and on masked evaluation of 
photographs, as summarized in Table 2. Median time to 
lesion scarring on masked evaluation of photographs was 
71.5 days (interquartile range (IQR) 57.5) for azithromy-
cin versus 36 days (IQR 25.5) for sulfadiazine/pyrimeth-
amine, while time to disease inactivity was 73 days (IQR 
61.25) versus 49 days (IQR 42.5), respectively. However, 
none of the differences in the above times reached statis-
tical significance. Demonstrating statistical non-inferiority 
between the 2 treatment regimens would require a consid-
erably larger sample size. Interestingly, no statistically signif-
icant difference was observed concerning total prednisone 
dose/ body weight received by patients in the 2 treatment 
arms (p=0.185). The adjusted p-values for multiple com-
parisons yield similar results in terms of statistical signifi-
cance. On the other hand, overall treatment tolerance was 
much better for patients who received the azithromycin-
containing regimen (p=0.0005), with a median treatment 
tolerance of 8.5 on the visual analogue score (VAS) for the 
azithromycin group as opposed to 3 for the sulfadiazine/
pyrimethamine group.
All patients were included in the analysis as appropriate in 
an intention-to-treat model, including the single patient 
on azithromycin that failed to respond to treatment and 
was eventually switched to the combination of sulfadiazine 
and pyrimethamine. Time to specific end-points was there-
fore significantly higher for that patient in comparison to 
all other patients in the analysis (time to disease inactivi-
ty of 235 days).
The Bland-Altman method revealed that the differences of 
measurements, within ±1.96 standard deviations, of time to 
lesion scarring between the 2 methods used (clinical evalu-
ation and masked evaluation of fundus photographs) were 
not clinically important; therefore the 2 methods can be 
used interchangeably. This fact signifies the lack of a possi-
ble bias introduced by unmasked clinical evaluation in the 
context of the present study.
In terms of adverse events, 1 patient developed a skin rash 
45 days after treatment initiation with sulfadiazine/pyri-
methamine. As a consequence, treatment was discontin-
ued at that point, which coincided with disease inactivity 
for that particular patient. All patients treated with sulfadi-
azine/pyrimethamine reported weak treatment tolerance, 
with symptoms including malaise, dizziness, headaches and 
gastrointestinal disorders. However, no major adverse events 
such as bone marrow depression were observed in patients 
receiving sulfadiazine/pyrimethamine.
Treatment failure was documented in 1 patient in the 
azithromycin arm. Over the course of treatment, that pa-
tient exhibited persistence of inflammatory reaction and 
progressive increase in lesion size, with no signs of scarring. 
Group Azithromycin Group Sulfadiazine/ Pyrimethamine
N=10 N=9
Continuous variables Median (IQR) Median (IQR) p*
Change in lesion size
 (mm2)  –1,695.0 (2.325)  –3.51 (3.222) 0.072
 (%)  –44.4 (26.10)  –56.6 (24.40) 0.248
Time to sharpening of lesion borders
 clinical evaluation (days)  25.5 (23.00)  24.0 (13.50) 0.870
 masked evaluation of photographs (days)  30.5 (30.75)  24.0 (17.00) 0.270
Time to lesion scarring
 clinical evaluation (days)  73.0 (57.25)  47.0 (14.00) 0.236
 masked evaluation of photographs (days)  71.5 (57.50)  36.0 (25.50) 0.307
Time to disease inactivity (days)  73.0 (61.25)  49.0 (42.50) 0.540
Treatment tolerance (VAS score)  8.5 (5.00)  3.0 (4.00) 0.0005
Categorical variables n (%) n (%) p**
Treatment Failure  1.0 (10.00)  0.0 (0.00) >0.999F
Table 2. Comparison of main outcome measures between the two groups.
* value from Mann-Whitney-Wilcoxon test for independent samples; ** value derived from Fisher’s exact test; IQR – inter-quartile range; 
VAS – visual analogue score.
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Seventy-two days after the initiation of treatment, the patient 
was switched to sulfadiazine/pyrimethamine, with eventu-
ally favorable clinical response.
All patients were included in the statistical analysis in an in-
tention-to-treat approach. However, no statistically signifi-
cant difference in treatment failure rate could be identified 
between the 2 treatment groups. (p>0.999)
discussion
Azithromycin monotherapy appeared to be an efficient treat-
ment option for non-vision-threatening toxoplasmic retino-
choroiditis leading to lesion scarring and disease inactivity 
in all but 1 patient. Disease remission required longer du-
ration of treatment with azithromycin as opposed to sulfa-
diazine/pyrimethamine in a clinically, but not statistically, 
significant way. On the other hand, treatment tolerance was 
significantly better in the azithromycin arm of the study.
Any attempt to compare therapeutic options for ocular 
toxoplasmosis is subject to substantial difficulties stemming 
from the self-limiting nature of the disease. A combination 
of host, parasite and environmental factors influences se-
verity of disease presentation, making it difficult to clearly 
identify the characteristics of the ideal drug for ocular toxo-
plasmosis [2]. A strict randomization process, as employed 
in this study, is required to eliminate the effect of potential 
confounding factors such as age [21].
The ability of any treatment regimen to alter the natural his-
tory of toxoplasmic retinochoroiditis has not been unequiv-
ocally demonstrated so far. In a systematic review of the lit-
erature by Stanford et al, only 3 prospective, randomized, 
placebo-controlled clinical trials for the treatment of ocu-
lar toxoplasmosis in immunocompetent patients could be 
identified [22]. None of these studies clearly confirmed the 
efficacy of short-term drug therapy for active toxoplasmic 
retinochoroiditis. However, clinical observation and expe-
rience have led uveitis specialists to consider the potential 
benefits of treating ocular toxoplasmosis in terms of reduc-
tion in lesion size and disease duration.
Several studies have attempted to assess the efficacy of vari-
ous antiparasitic drug combinations in the treatment of oc-
ular toxoplasmosis. Investigated agents include currently 
used treatment options for toxoplasmic retinochoroiditis, 
such as pyrimethamine and sulfadiazine, clindamycin per os 
[23–25] and intravitreal [26], trimethoprim-sulfamethoxa-
zole [19,27], atovaquone [28,29] or various combinations of 
the above and even quadruple therapy (30). Corresponding 
studies claimed to shorten the duration of active disease in 
toxoplasmic retinochoroiditis. However, different study de-
signs, absence of controls and substantial variation in the 
choice of outcomes for the evaluation of treatment efficacy 
render the comparison of these studies difficult.
The best clinical results reported so far in the management 
of ocular toxoplasmosis involve the combination of pyri-
methamine and sulfadiazine [31]. Both sulfadiazine and 
pyrimethamine interfere at distinct stages of the folate cy-
cle, thus enhancing their common action. Their synergis-
tic activity in ocular toxoplasmosis has been documented in 
animal models, rendering this combination most effective 
and recommended for the treatment of vision-threatening 
toxoplasmosis [31]. Similar mechanism of action, however, 
leads to analogous adverse effects, such as bone marrow de-
pression. Potential weak tolerance of this antiparasitic com-
bination prompted investigators to look for alternative ther-
apeutic options with less adverse effects.
The role of azithromycin as a therapeutic agent in infec-
tions with T. gondii has been supported by several studies 
and has proven effective in the treatment of active toxoplas-
mosis in several animal models [16]. Azithromycin alone or 
in combination with pyrimethamine has beneficial effects 
for the treatment of toxoplasmic encephalitis in patients 
with AIDS, is well tolerated in adults and children, and has 
a low incidence of adverse events [32].
Few reports deal with azithromycin in the management 
of ocular toxoplasmosis. A pilot study showed a favorable 
response, defined as waning of initial inflammation with-
in 4 weeks after treatment initiation, to a 5-week course of 
azithromycin in 7 out of 11 patients presenting with active 
toxoplasmic retinochoroiditis in various locations [17]. 
In a prospective, randomized trial of pyrimethamine and 
azithromycin versus pyrimethamine and sulfadiazine for the 
treatment of sight-threatening ocular toxoplasmosis [18], 
the efficacy of a short-term multidrug regimen containing 
azithromycin was similar to standard therapy, with signifi-
cantly fewer and less severe adverse events in the azithro-
mycin-containing treatment group.
A randomized controlled study appeared essential to bet-
ter define the therapeutic role of azithromycin mono-
therapy in ocular toxoplasmosis. Despite substantial evi-
dence of the efficacy of azithromycin against T. gondii, we 
deemed it insufficient to support the treatment of vision-
threatening toxoplasmic retinochoroiditis with azithromy-
cin alone. We therefore preferred to include patients with 
non-vision-threatening toxoplasmic retinochoroiditis and 
to compare the efficacy of azithromycin versus classic ther-
apy in this group of patients. The potential benefits for pa-
tients from documenting the efficacy of azithromycin for 
the treatment of ocular toxoplasmosis include a simpler 
treatment regimen with fewer pills per day, better tolera-
bility and fewer adverse events.
In accordance with Bosch-Driessen et al. [18], we chose a 
dosage of azithromycin based on 2 in vitro studies, showing 
that concentration of azithromycin in brain tissue of pa-
tients with brain tumors 48 hours after the administration 
of 500 mg of azithromycin reached a level of 3.64±3.81 µg/g 
[33,34]. This value is between the IC 50 and IC 90 (50% 
and 90% inhibitory concentrations, respectively) for par-
asite growth in the presence of pyrimethamine. However, 
this concentration of azithromycin barely reached the IC 
50 for parasite growth when used alone in the same study 
[34]. The study by Tseng et al. [35] for the treatment of a 
Mycobacterium avium complex infection in HIV+ patients with 
azithromycin at a dose of 600 mg per day revealed a 17% 
incidence of ototoxicity. The dosage used in our study was 
therefore supposed to allow sufficient tissue concentrations 
of azithromycin, while assuring a decreased risk of adverse 
events, notably ototoxicity. The dosage of sulfadiazine/ py-
rimethamine that was chosen matched the common prac-
tices of a majority of clinicians [36].
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Although 1or several clinically-relevant surrogates of treat-
ment efficacy have yet to be determined in toxoplasmic ret-
inochoroiditis, we agree with Holland [37] that the time in-
terval to sharpening of lesion borders and the time interval 
to disease inactivity may be more appropriate primary out-
come measures for treatment efficacy. Visual acuity, on the 
other hand, is not a reliable outcome measure, largely de-
pending on lesion location. In particular, since the present 
study included only non-vision-threatening lesions, change 
in visual acuity at the end of follow-up yields less valuable 
information in terms of treatment efficacy.
Although patients on azithromycin monotherapy exhibited 
response to treatment with eventual lesion scarring and dis-
ease inactivity, clinical observation revealed a significantly in-
creased duration of treatment for these patients as opposed 
to the group treated with sulfadiazine/pyrimethamine. This 
increased duration of treatment with azithromycin could 
not be statistically verified in view of the small study sample. 
Differences in initial lesion size may also in part justify this 
discrepancy, as they significantly influence the duration of 
treatment in toxoplasmic retinochoroiditis. In the context 
of the present pilot study, sample size would not allow for 
establishing non-inferiority between the 2 treatment regi-
mens. Although a strong statistically significant difference 
in outcome measures of treatment efficacy would indeed 
point to true differences in efficacy between the 2 treatment 
regimens, the absence of such statistically significant differ-
ences cannot convincingly establish the equivalence of the 
2 regimens. Despite longer treatment duration, no signif-
icant adverse events or patient discomfort with treatment 
were identified for the azithromycin group.
None of the previously described severe adverse events of 
the standard treatment regimen of sulfadiazine/pyrimeth-
amine was observed, in contrast to the high rate of bone 
marrow depression reported in other studies [3,38]. Minor 
adverse effects of this regimen were, on the other hand, rath-
er common, leading to a statistically significant difference 
in treatment tolerance and patient comfort with treatment 
between the 2 arms of the study. In contrast, azithromycin 
was well tolerated by all patients, with no minor or major 
adverse events observed.
One patient treated with azithromycin failed to respond 
to treatment. Although several causes for such a phenom-
enon could be hypothesized, including infection with a re-
sistant strain of T. gondii, poor compliance to treatment is 
the most likely explanation. On the other hand, the rate 
of treatment failure was not statistically significantly differ-
ent between the 2 treatment arms. This patient was also 
included in the statistical analysis in an intention-to-treat 
approach. Such an analysis allows for circumventing a po-
tential bias arising from the exclusion of patients with poor 
response to investigated treatment.
This study has certain limitations. Given that this is a first at-
tempt to evaluate the efficacy of azithromycin alone for the 
management of ocular toxoplasmosis, the inclusion criteria 
chosen were strict, thus limiting the number of recruited pa-
tients. A meaningful limitation of the present study resides 
in the small numbers, rendering proper non-inferiority sta-
tistics inapplicable. Significantly higher numbers, however, 
are unlikely to be achieved in the context of posterior uveitis, 
especially on an institutional basis. Fair conclusions of the 
present study would therefore be that azithromycin mono-
therapy is efficient for the treatment of non-vision-threaten-
ing toxoplasmic retinochoroiditis, while being significantly 
better tolerated than sulfadiazine/pyrimethamine, and that 
treatment duration appeared clinically to be longer for the 
azithromycin group. Proposed statistical associations concern-
ing the comparison of the 2 treatment regimens in respect 
to efficacy are to be considered merely descriptive. Further 
limitations of the present study include the absence of a pla-
cebo-controlled arm and the fact that both examiners and 
patients were unmasked to treatment; these factors may in-
fluence interpretation of drug adverse events and may af-
fect the identification of the time points of lesion scarring 
and disease inactivity. To offset this limitation, a masked 
evaluation of fundus photographs by an independent oph-
thalmologist was performed in order to minimize bias that 
could arise from unmasked clinical evaluation. The statisti-
cal comparison of measurements obtained by clinical evalu-
ation and masked evaluation of photographs did not reveal 
a clinically important disparity of the 2 methods.
conclusions
Azithromycin alone for active, non-vision-threatening toxo-
plasmic retinochoroiditis led to disease remission in all but 
1 case, although requiring a longer duration of treatment 
as opposed to sulfadiazine/pyrimethamine. Additionally, 
subjective reporting of adverse events by patients showed 
that azithromycin was much better tolerated. Therefore, 
azithromycin may be a valuable and reasonable alternative 
in the management of active, non-vision-threatening toxo-
plasmic retinochoroiditis. Given the increased interest in 
the use of azithromycin for toxoplasmic retinochoroiditis 
observed in recent years, this pilot study offers valuable ev-
idence in support of the inclusion of azithromycin in the 
pharmaceutical armamentarium against ocular toxoplas-
mosis. Whether better treatment tolerance of azithromycin 
is adequate an advantage to offset the need for longer du-
ration of treatment is open for debate. A multicenter trial 
would serve to verify and refine these findings.
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